Status:
COMPLETED
HFIP Ex-vivo Study
Lead Sponsor:
University of Zurich
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
Sepsis, a multi organ failure caused by infectious diseases, is a major health burden with an average mortality rate of 26%. Cells of the innate immune system of hosts recognize specific patterns of p...
Eligibility Criteria
Inclusion
- Patients admitted to the emergency ward with suspicion of infection and a qSOFA Score ≥ 2 points (Respiratory frequency \> 22/minute, Systolic blood pressure \< 100 mmHg, Glasgow Coma Scale \< 15).
- Male and Female subjects with at least 18 years of age.
- Written informed consent by the participant after information about the project. In emergency cases where a written consent cannot be obtained immediately, due to the patient's medical conditions, the existence of a patient decree and of a representative in the emergency situation is evaluated according to the Swiss Civil Code. Informed consent will be obtained from the representative. A medical doctor, furthermore, not participating in the investigation, guarantees the medical care of the patient by the defending of his/her interests. After recovery, the patient will be informed as soon as possible about the trial and consent is requested.
Exclusion
- Acquired Immune Deficiency Syndrome
- Anti-IL-6 therapy (e.g. Kevzara®) within the last 60 days
- Application of a cytokine absorber
- Pregnancy and/or Breast feeding
Key Trial Info
Start Date :
August 5 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 26 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04059263
Start Date
August 5 2019
End Date
June 26 2024
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland, 8091